Advances in Precision Medicine: Targeting Known and Emerging Oncogenic Targets in Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (20 March 2024) | Viewed by 12873
Special Issue Editor
Special Issue Information
Dear Colleagues,
The landscape for the diagnosis and treatment of lung cancer has significantly evolved over the past two decades. The current era of precision medicine in resectable early-stage and non-operable advanced-stage NSCLC mandates the pathohistological evaluation and molecular biomarker testing of tumor specimens at diagnosis. Increasingly, subsequent biomarker testing is essential for selecting appropriate treatment at timepoints of tumor progression throughout the disease course. Significant progress has also been made in expanding the armamentarium of targeted therapies from small molecule tyrosine kinase inhibitors and monoclonal antibodies to covalent bound inhibitors, bispecific antibodies, and antibody–drug conjugants for both known and emerging oncogenic targets. The clinical implementation of precision medicine in lung cancer requires the close collaboration of a multidisciplinary team, along with further technology and knowledge advances in understanding tumor biology and biomarker-guided treatment selection at the patient level. This Special Issue will focus on a series of reviews on recent advances in targeting known and emerging oncogenic targets (such as MET, HER2, and KRAS genomic alterations) in lung adenocarcinomas, lung squamous cell carcinoma, neuroendocrine, small cell lung cancer, and malignant pleural mesothelioma.
Prof. Dr. Tianhong Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- precision oncology
- lung cancer
- oncogenic target
- targeted therapy
- biomarker
- diagnosis